Related references
Note: Only part of the references are listed.Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis
Mark B. Geyer et al.
BLOOD (2017)
Burden of hospitalization in relapsed acute lymphoblastic leukemia
A. Barlev et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2016)
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
Gillian D. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
N. Goekbuget et al.
BLOOD CANCER JOURNAL (2016)
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2016)
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective
Andrzej J. Jakubowiak et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden
Aaron J. Katz et al.
CANCER CAUSES & CONTROL (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation: An Alternative Approach
Adrian Bagust et al.
MEDICAL DECISION MAKING (2014)
In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival
Peter A. Ubel et al.
HEALTH AFFAIRS (2012)
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
Alison Stopeck et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Health Care Costs for Patients With Cancer at the End of Life
Benjamin Chastek et al.
JOURNAL OF ONCOLOGY PRACTICE (2012)
Deriving a Preference-Based Measure for Cancer Using the EORTC QLQ-C30
Donna Rowen et al.
VALUE IN HEALTH (2011)
A population-based cytogenetic study of adults with acute lymphoblastic leukemia
Anthony V. Moorman et al.
BLOOD (2010)
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group
Albert Oriol et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Adjusting the value of a statistical life for age and cohort effects
Joseph E. Aldy et al.
REVIEW OF ECONOMICS AND STATISTICS (2008)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Adele K. Fielding et al.
BLOOD (2007)
Preference-based EQ-5D index scores for chronic conditions in the United States
Patrick W. Sullivan et al.
MEDICAL DECISION MAKING (2006)
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
JM Rowe et al.
BLOOD (2005)
Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma
BE Hillner et al.
CANCER (2005)
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
H Kantarjian et al.
CANCER (2004)
Share Paper
